[4-(4-Cyclohexylbutyl)pyridin-2-yl] hydrogen carbonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [4-(4-Cyclohexylbutyl)pyridin-2-yl] hydrogen carbonate
• 英文别名: [4-(4-cyclohexylbutyl)pyridin-2-yl] hydrogen carbonate
• 化学式: C₁₆H₂₃NO₃
• 分子量: 277.36
• InChiKey: SHFVQFFVMLXREJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] FIXED DOSE COMBINATION TREATMENT FOR SCHIZOPHRENIA<br/>[FR] POLYTHÉRAPIE À DOSES PRÉDÉTERMINÉES POUR LA SCHIZOPHRÉNIE
  申请人：SHIRE LLC

  公开号：WO2014144115A1

  公开（公告）日：2014-09-18

  The present invention relates to a fixed dosage unit, and methods for treating schizophrenia comprising administering the fixed dosage unit. More specifically, the present invention relates to a fixed dosage unit that reduces the incidence or degree of adverse effects that are associated with atypical antipsychotic drug therapy. The present invention relates to the field of pharmaceutical dosage forms and methods for treatment.
• [EN] FIXED DOSE COMBINATION TREATMENT FOR SCHIZOPHRENIA<br/>[FR] POLYTHÉRAPIE À DOSE FIXÉE POUR LA SCHIZOPHRÉNIE
  申请人：SHIRE LLC

  公开号：WO2014168727A1

  公开（公告）日：2014-10-16

  The present invention relates to a fixed dosage unit, and methods for treating schizophrenia comprising administering the fixed dosage unit. More specifically, the present invention relates to a fixed dosage unit that reduces the incidence or degree of adverse effects that are associated with atypical antipsychotic drug therapy. The present invention relates to the field of pharmaceutical dosage forms and methods for treatment. More particularly, the present invention relates to a fixed dosage unit including lisdexamfetamine dimesylate and an atypical antipsychotic drug, and methods for treating schizophrenia comprising administering the fixed dosage unit.